Doloromics is a technology company.
Doloromics has raised $8.0M across 2 funding rounds.
Doloromics has raised $8.0M in total across 2 funding rounds.
Doloromics has raised $8.0M in total across 2 funding rounds.
Doloromics's investors include Mayfield, SOSV, Illumina Accelerator.
Doloromics is a biotechnology company specializing in precision neuropharmaceuticals aimed at developing targeted medicines for chronic pain. Founded in 2020 and based in Addison, Texas, Doloromics uses a proprietary platform integrating deep neuroscience, transcriptomics, and bioinformatics to identify novel therapeutic targets. Their approach focuses on understanding molecular mechanisms of chronic pain to create non-opioid treatments that modify disease pathways, serving the healthcare industry with innovative precision medicines. The company is expanding its pipeline with multiple preclinical assets targeting conditions like rheumatoid arthritis, migraine, fibromyalgia, and cancer pain, showing promising growth momentum in the neuropharmaceutical space[1][2][3][5].
Doloromics was co-founded by Jackson Brougher, who brings a strong scientific and entrepreneurial background. The idea emerged from leveraging advanced omics technologies—such as single-cell transcriptomics and proteomics—to better understand neurological disease progression and pain mechanisms. Early traction came through acceptance into the Illumina Accelerator, which provided seed funding, sequencing technology access, and lab space critical for their initial research. Since then, Doloromics has established its own lab in Menlo Park, California, and is actively building out its therapeutic pipeline while seeking further investment to scale[3][4].
Doloromics rides the growing trend of precision medicine and neuropharmaceutical innovation, leveraging breakthroughs in omics technologies and computational biology. The timing is critical as chronic pain remains a major unmet medical need globally, compounded by the opioid epidemic and demand for safer, more effective treatments. Advances in single-cell transcriptomics and bioinformatics enable Doloromics to dissect complex neurological diseases at unprecedented resolution, positioning it as a pioneer in precision pain therapeutics. Their work influences the broader biotech ecosystem by demonstrating how integrated omics and computational platforms can accelerate drug discovery and reshape chronic disease treatment paradigms[1][3][6].
Looking ahead, Doloromics is poised to advance its preclinical candidates toward clinical development, potentially setting new standards for chronic pain management. Trends such as increased adoption of precision neuropharmaceuticals, regulatory support for non-opioid analgesics, and growing investment in biotech innovation will shape their trajectory. As they expand beyond chronic pain into other neurological disorders, Doloromics could significantly influence how neurological diseases are understood and treated, reinforcing their role as a leader in precision neuroscience. Their success may encourage wider industry adoption of omics-driven drug discovery, amplifying their impact on the startup and biotech ecosystem[1][3][4].
Doloromics has raised $8.0M across 2 funding rounds. Most recently, it raised $7.0M Seed in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $7.0M Seed | Mayfield, SOSV | |
| Feb 1, 2021 | $1.0M Seed | Illumina Accelerator |